Genomma Lab Internacional SAB de CV (LABB) Stock Price & Analysis

LABB Stock Chart & Stats

MX$15.17MX$0.26(1.74%)

At close: Oct 30 3:59 PM EDT

Day’s Range: MXN 14.60 - MXN 15.19
52-Week Range: MXN 12.22 - MXN 19.48
Previous Close: MXN 14.91
Volume: N/A
Average Volume (3M): 4.29M
Market Cap: MXN 15.14B
Enterprise Value: MXN 17.56B
Total Cash (Recent Filing): MXN 2.74B
Total Debt (Recent Filing): MXN 8.06B
Price to Earnings (P/E): 8.8
Beta: 0.97
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: 0.44
Last Dividend Ex-Date: Sep 29, 2026
Dividend Yield: 5.28%

Genomma Lab Internacional SAB de CV News

Genomma Lab Ratifies Deloitte as 2026 External Auditor

Genomma Lab Internacional SAB de CV ( ($MX:LABB) ) has provided an update. Genomma Lab Internacional has ratified the appointment of Galaz, Yamazaki, Ruiz Urquiza, S.C., known as Deloitte, as

3d agoGNMLF GEKA

Genomma Lab Denies Insider Role in Unusual LABB Trading Surge

Genomma Lab Internacional SAB de CV ( ($MX:LABB) ) has issued an announcement. Genomma Lab Internacional reported that the unusual spike in trading volume of its LAB B shares observed

5d agoGNMLF GEKA

Genomma Lab Earnings Call Signals Gradual Recovery

Genomma Lab Internacional SAB de CV Class B (($MX:LABB)) has held its Q3 earnings call. Read on for the main highlights of the call. Genomma Lab Internacional’s latest earnings call

1w agoGNMLF GEKA

Genomma Lab Corrects 2025 Comparative Figures in Q3 2026 Report

The latest announcement is out from Genomma Lab Internacional SAB de CV ( ($MX:LABB) ). Genomma Lab Internacional has retransmitted its third-quarter 2026 financial information to correct comparative figures for

1w agoGNMLF GEKA

Genomma Lab Signals Early Recovery as Latin America Growth Offsets U.S. Weakness

An announcement from Genomma Lab Internacional SAB de CV ( ($MX:LABB) ) is now available. Genomma Lab reported third-quarter 2026 results that signal an early recovery, with consolidated net sales

1w agoGNMLF GEKA

GNMLF Upcoming Earnings Report: What to Expect?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 3rd quarter earnings on 10/21/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Genomma

2w agoGNMLF GEKA

Genomma Lab Sets Seventeenth Dividend, Reaffirms Quarterly Payout Strategy

An announcement from Genomma Lab Internacional SAB de CV ( ($MX:LABB) ) is now available. Genomma Lab Internacional, a major Mexican pharmaceutical and personal care products company, focuses on premium

1M agoGNMLF GEKA

Genomma Lab Founder to Lead AI-Driven Operating Shift as Interim CEO

Genomma Lab Internacional SAB de CV ( ($MX:LABB) ) has shared an update. Genomma Lab Internacional has announced a planned management transition, naming founder and current chairman Rodrigo Herrera Aspra

1M agoGNMLF GEKA

Genomma Lab Earnings Call Balances Pressure and Recovery

Genomma Lab Internacional SAB de CV Class B (($MX:LABB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genomma Lab Internacional’s latest earnings call

3M agoGNMLF GEKA

GNMLF Earnings this Week: How Will it Perform?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 2nd quarter earnings on 07/22/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Genomma

3M agoGNMLF GEKA

Genomma Lab initiated with a Hold at Jefferies

Jefferies initiated coverage of Genomma Lab (GNMLF) with a Hold rating and MXN 16 price target The firm cites the company’s recent operational challenges and limited visibility on near-term catalysts

3M agoGNMLF GEKA

Genomma Lab upgraded to Buy from Neutral at BTG Pactual

BTG Pactual upgraded Genomma Lab to Buy from Neutral with a MXN 28 price target. The firm sees a strong earnings outlook and attractive valuation. Published first on TheFly –

2y agoGNMLF GEKA

Genomma Lab downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Antonio Hernandez downgraded Genomma Lab to Equal Weight from Overweight with a price target of MXN 17, down from MXN 23. The analyst downgraded the shares post the

3y agoGNMLF GEKA

Genomma Lab downgraded to Neutral from Buy at UBS

UBS analyst Rodrigo Alcantara downgraded Genomma Lab to Neutral from Buy with a price target of MXN 18, down from MXN 24. Published first on TheFly See the top stocks

3y agoGNMLF GEKA

LABB FAQ

What was Genomma Lab Internacional SAB de CV’s price range in the past 12 months?

Genomma Lab Internacional SAB de CV lowest stock price was Mex$12.22 and its highest was Mex$19.48 in the past 12 months.

What is Genomma Lab Internacional SAB de CV’s market cap?

Genomma Lab Internacional SAB de CV’s market cap is Mex$15.14B.

When is Genomma Lab Internacional SAB de CV’s upcoming earnings report date?

Genomma Lab Internacional SAB de CV’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 114 days.

How were Genomma Lab Internacional SAB de CV’s earnings last quarter?

Genomma Lab Internacional SAB de CV released its earnings results on Oct 21, 2026. The company reported Mex$0.51 earnings per share for the quarter, beating the consensus estimate of Mex$0.39 by Mex$0.12.

Is Genomma Lab Internacional SAB de CV overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Genomma Lab Internacional SAB de CV pay dividends?

Genomma Lab Internacional SAB de CV pays a Quarterly dividend of Mex$0.2 which represents an annual dividend yield of 5.28%. See more information on Genomma Lab Internacional SAB de CV dividends here

What is Genomma Lab Internacional SAB de CV’s EPS estimate?

Genomma Lab Internacional SAB de CV’s EPS estimate is 0.44.

How many shares outstanding does Genomma Lab Internacional SAB de CV have?

Genomma Lab Internacional SAB de CV has 1,000,000,000 shares outstanding.

What happened to Genomma Lab Internacional SAB de CV’s price movement after its last earnings report?

Genomma Lab Internacional SAB de CV reported an EPS of Mex$0.51 in its last earnings report, beating expectations of Mex$0.39. Following the earnings report the stock price went up 2.086%.

Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV?

Currently, no hedge funds are holding shares in MX:LABB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genomma Lab Internacional SAB de CV

Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.

Genomma Lab Internacional SAB de CV (LABB) Earnings & Revenues

Historic Earnings Reports

LABB Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call conveyed a cautiously optimistic recovery narrative. Mexico sellout, market share, innovation, Latin America growth, cash flow, liquidity, and debt maturity improvements were significant positives, while the United States remained difficult, margins contracted, working capital increased, Brazil faced tax-reform-related inventory pressure, and part of net income growth came from a nonrecurring foreign exchange gain. Management characterized the quarter as mixed but emphasized that the recovery plan was working and that sellout improvement was underway.

View all MX:LABB earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	14	6	2
Technical Analysis	3	6	1
Moving Averages	11	0	1

Technical Analysis >

Similar Stocks

Stocks similar to MX:LABB
Company	Price & Change	Follow
LSCCLattice Semiconductor
DSGRDistribution Solutions Group

Compare MX:LABB Stocks >

Ownership Overview

9.47% Mutual Funds
<0.01% Other Institutional Investors
83.32% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

LABB Stock Chart & Stats

Genomma Lab Internacional SAB de CV News

Genomma Lab Ratifies Deloitte as 2026 External Auditor

Genomma Lab Denies Insider Role in Unusual LABB Trading Surge

Genomma Lab Earnings Call Signals Gradual Recovery

Genomma Lab Corrects 2025 Comparative Figures in Q3 2026 Report

Genomma Lab Signals Early Recovery as Latin America Growth Offsets U.S. Weakness

GNMLF Upcoming Earnings Report: What to Expect?

Genomma Lab Sets Seventeenth Dividend, Reaffirms Quarterly Payout Strategy

Genomma Lab Founder to Lead AI-Driven Operating Shift as Interim CEO

Genomma Lab Earnings Call Balances Pressure and Recovery

GNMLF Earnings this Week: How Will it Perform?

Genomma Lab initiated with a Hold at Jefferies

Genomma Lab upgraded to Buy from Neutral at BTG Pactual

Genomma Lab downgraded to Equal Weight from Overweight at Barclays

Genomma Lab downgraded to Neutral from Buy at UBS

LABB FAQ

Company Description

Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV (LABB) Earnings & Revenues

LABB Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive